Kornimate/medical-research-clean huggingface dataset:
clinical impact of second-look endoscopy after endoscopic submucosal dissection of gastric neoplasm

Conditions: Gastric Neoplasms

Summary: gastroenterologists often follow up second look endoscopy after endoscopic submucosal dissection(esd) of gastric neoplasms because they want to prevent bleeding of procedure sites. but goto suggested in his retrospective analysis that a second-look endoscopy after endoscopic submucosal dissection for gastric epithelial neoplasm may be unnecessary. so, the investigators try to identify the hypothesis prospectively in this study.


Eligibility criteria:
inclusion criteria: * histological confirmed patients(gastric adenoma or adenocarcinoma) * performed gastric esd patients about 24 hours before exclusion criteria: * perforation after esd * piecemeal resection of esd specimen * hemostatic agent or proton pump inhibitor users before esd * heparin or antiplatelet agent users * serious concurrent infection or nonmalignant illness that is uncontrolled * psychiatric disorder that would preclude compliance * allergy history to proton pump inhibitor

Keywords: endoscopic submucosal dissection gastric neoplasm second look endoscopy
orientation characteristics of kalifilcon a daily disposable toric contact lenses compared to acuvue oasys 1-day for astigmatism contact lenses

Conditions: Astigmatism

Summary: approximately 30 soft toric contact lens adapted subjects will be enrolled in this feasibility, bilateral, randomized, double-masked (subject and investigator), repeated measures insertion study. all subjects will be seen for a screening/dispensing visit at which informed consent will be obtained and eligibility will be assessed. if subjects satisfy all eligibility criteria, subjects will be dispensed study lenses according to unique randomization tables that will be provided to each investigator. if study eligibility is met, subjects will have lenses inserted in random, successive order. subjects will be receiving each of the study lens types once, in a randomized order. the subject will wear each of the study contact lenses for approximately 10 minutes.


Eligibility criteria:
inclusion criteria: 1. be 18 years or older on the date the informed consent form (icf) is signed and have capacity to read, understand and provide written voluntary informed consent. 2. have physiologically normal anterior segments not exhibiting clinically significant biomicroscopy findings. 3. have no active ocular disease or allergic conjunctivitis 4. not be using any topical ocular medications. 5. be willing and able to follow instructions. 6. have signed a statement of informed consent. exclusion criteria: the subject is not eligible to participate in the study if the subject is: 1. participating in a conflicting study in the opinion of the investigator. 2. considered by the investigator to not be a suitable candidate for participation.
testing the effectiveness of cognitive training among depressed patients receiving esketamine treatment

Conditions: Depression

Summary: in a sample of patients already receiving esketamine treatment as part of their clinical care, this project seeks to test whether we can improve depression by introducing helpful information delivered by a computer-based training protocol. this work could ultimately lead to the ability to treat depression more efficiently and with broader dissemination by rapidly priming the brain for helpful forms of learning.


Eligibility criteria:
inclusion criteria: any patient aged 18-80 in the esketamine clinic in the center for interventional psychiatry. the clinic's extensive screening and eligibility criteria for esketamine treatment will not be altered in any way, other than imposing the study-specific age range and the two exclusion criteria below. exclusion criteria: 1. patients who do not expect to remain located in the pittsburgh area for a minimum of 1 month beyond study enrollment. 2. patients who, in the judgment of the esketamine clinical medical director, show signs of intellectual disability, developmental disability, and/or cognitive impairment (including age-related cognitive decline) of a sufficient degree to interfere with engagement in any study procedure.
a study to learn about how safe and effective is 20vpnc and 13vpnc vaccines in chinese adults

Conditions: Pneumococcal Disease

Summary: this phase 1, randomized, double-blind, third-party-unblinded study will be conducted at investigational sites in china. the purpose of the study is to learn about the safety and immune response of 20vpnc and 13vpnc in chinese adults 50 years of age and older who did not receive any of pneumococcal vaccine in the past

the purpose of the study is to learn about the safety and immune response of 20vpnc and 13vpnc vaccines in chinese adults. this study is seeking for participants who: * are 50 years of age and older * did not receive any of vaccines used to treat infections caused by the bacteria called streptococcus pneumonia in the past. the participants will be grouped by three age groups: * adults between 50 to 59 years of age * adults between 60 to 64 years of age * adults who are 65 years of age or above all participants in this study will receive a single dose of 20vpnc or 13vpnc at study clinic. the study will look at the experiences of people receiving 20vpnc and 13vpnc. this will help decide if the study vaccine is safe. the total duration of taking part in the study will be around 6 months, with 6 visits.

Eligibility criteria:
key inclusion criteria: 1.generally healthy adults including those with preexisting stable disease determined to be eligible based on clinical assessment, medical history and clinical judgment. key exclusion criteria: 1. history of microbiologically-proven invasive disease caused by streptococcus pneumoniae 2. previous vaccination with any licensed or investigational pneumococcal vaccine or planned receipt through study participation.
regenerative cardiosphere injection to strengthen dysfunctional hearts

Conditions: Ischemic Cardiomyopathy; Chronic Ischemic Cardiomyopathy

Summary: a double blinded and placebo-controlled, dose escalation, single-center safety and preliminary efficacy study of cardiospheres delivered via noga myostar injection catheter in subjects with chronic ischemic cardiomyopathy. the objective is to achieve and document myocardial regeneration in patients with chronic scar.


Eligibility criteria:
inclusion criteria: * adults with ischemic cardiomyopathy (ef \>10 and \<40% by functional imaging \[echo, ct, mri, contrast ventriculography\]) * symptomatic heart failure of nyha class 2 or 3 * history of prior remote (\>3 mo) myocardial infarction and/or documented obstructive coronary artery disease with corresponding dysfunctional segments by functional imaging * age \> 18 years * ability to provide informed consent and follow-up with protocol procedures exclusion criteria: * documented myocardial infarction within 3 months (120 days) * known or suspected left ventricular thrombus * non-cardiovascular disease with life expectancy of \< 3 years * absence of significant gadolinium-enhanced scar (\>10% of lv mass) at baseline mric * positive panel-reactive antibodies (pra) * need for further revascularization clinically indicated at the time the patient is assessed for participation in the clinical trial. this will be determined by a cardiologist who is not an investigator in the clinical trial. no further revascularization may be indicated by no arteries with significant stenosis, the location, and extent of any stenosis may not be suitable for angioplasty, the distal vessels may not be suitable for placement of bypass grafts, and/or the patient declines angioplasty or bypass surgery. * nyha iv heart failure * history of aortic stenosis/insufficiency * requirement for chronic immunosuppressive therapy * participation in an on-going protocol studying an experimental drug or device * diagnosis of congenital or genetically-transmitted cardiomyopathy * current alcohol or drug abuse because of anticipated difficulty in complying with protocol-related procedures * pregnancy or child-bearing potential without use of effective contraception. men intending to "father" children are also excluded. * human immunodeficiency virus infection * viral hepatitis * uncontrolled diabetes and/or hemoglobin a1c \> 8.5% * abnormal liver function (sgpt \> 3 times the upper reference range) and/or hematology (hematocrit \<25%, wbc \<3000, platelets \<100,000) studies without a reversible, identifiable cause * ventricular tachycardia or fibrillation not associated with an acute ischemic episode * canadian cardiovascular society angina class 3 or 4 * history of cardiac tumor or cardiac tumor demonstrated or suspected on mri other imaging modality * previous stem cell therapy/treatment * individuals who are not fluent in english

Keywords: infarction myocardial infarction ventricular dysfunction, left heart disease cardiovascular disease chronic ischemia
improving substance abuse counseling adherence using web-based videoconferencing

Conditions: Substance Abuse Disorder

Summary: this research is being done to compare the effectiveness of standard on-site, in-person counseling with internet web-based videoconferencing (e-therapy) in drug-dependent patients in opioid-agonist treatment programs. the study is looking to see if there are any differences in satisfaction or in treatment outcome if counseling sessions are given by e-therapy compared to standard, in-person counseling given in the clinic. the e-therapy happens in real time- it works very much like standard therapy in the clinic except that the patient is in his or her own home (or other convenient location outside the clinic) and talks to and sees the therapist through an internet connection on the computer (the therapist will usually be at the clinic).

this study will be the first to evaluate the efficacy of an accredited and currently available, internet web-based videoconferencing platform to deliver routine schedules of counseling in an opioid agonist treatment program. it has outstanding potential to help determine transportability of this technology to other treatment programs by demonstrating the benefits of integration of web-based therapy with on-site services to expand the continuum of care.

Eligibility criteria:
inclusion criteria: * access to a computer with internet capability * full adherence to their routine counseling schedule over the previous 30-days * negative urine specimens over the previous 30-days * patient at ats for 90 days exclusion criteria: * no access to a computer with internet capability

Keywords: web based videoconferencing methadone substance abuse counseling
outcomes of circuit training and low carbohydrates diet in the young obese male in ksa

Conditions: Obesity

Summary: obesity is one of the common public problems that its prevalence increase incredibly in the last three decades in ksa. thirty obese males aged 20 to 39 years will participate in the study. the participants will be evaluated on skinfold thickness, percent of body fat, lipid profile, and exercise capacity. all participants will perform a circuit training of aerobic and resistance exercises and be instructed to follow a low carbohydrate diet for eight weeks.


Eligibility criteria:
inclusion criteria: 1. obese young male subjects with a mass index between bmi \>30 kg/m2 and 40 kg/m2). 2. subjects ages range from 20 to 39 years. 3. previously sedentary, defined as no strength training and less than 150 minutes of brisk walking or moderate exercise per week and \< less than 60 minutes of vigorous exercise per week in the preceding 6 months. 4. only subjects who are nonsmokers. 5. subjects who are not taking insulin. 6. had no evidence or history of coronary artery disease. exclusion criteria: 1. subjects were excluded if they reported a history of heart disease, respiratory conditions, stroke, diabetes, recent cancer, other life-threatening illness, or any condition that limited their ability to engage in moderate-intensity exercise. 2. smoking
sap block to reduce post mastectomy pain

Conditions: Serratus Anterior Plain Block

Summary: to decrease post-operative pain in patients undergoing modified radical mastectomy.

the serratus anterior plane (sap) block has proven to be an effective component of multimodal analgesic regimens for a variety of thoracic procedures. it is designed to block primarily the thoracic intercostal nerves and to provide complete analgesia of the lateral part of the thorax and it may be a viable alternative to paravertebral blockade and thoracic epidural analgesia and may be associated with fewer side effects. it's straight forward to perform, with high success rate and minimal incidence of complications. it was reported prolonged numbness over the area supplied by the lateral cutaneous branches of the t2-t9 spinal nerves using only 0.4 ml.kg-10.125% levobupivacaine. this is remarkable, because alternative techniques such as intercostal, interpleural and thoracic paravertebral block require relatively high concentrations and volumes of local anesthetics to produce similarly prolonged, multi-dermatomal thoracic analgesia.the duration of serratus plane block is limited to the effect of administered local anesthetics (las). however, recently adjuvants such as epinephrine, ketamine and clonidine are added to la solution in concentrations advocated for other peripheral blocks to prolong the effect of block with promising results. evidence supporting the presence of n-methyl-d-aspartate (nmda) receptors in skin and muscles have led to the use of magnesium sulphate (mgso4) (nmda antagonist) via different routes for brachial plexus block and via neuraxial route. until date, no study has been done to evaluate the role of mgso4 as an adjuvant in sap block. therefore, the investigators intended this study to evaluate the role of mgso4 as an adjuvant to bupivacaine in ultrasound (usg)-guided sap block for postoperative analgesia in patients scheduled for modified radical mastectomy. while the key requirement for successful regional anesthetic blocks is ensuring optimal distribution of local anesthetic around nerve structures, ultrasound guidance enables the anesthetist to secure an accurate needle position and to monitor the distribution of the local anesthetic in real time.

Eligibility criteria:
inclusion criteria: * adult, female patients, asa physical status i, ii, and iii aged older than 18 years scheduled for modified radical mastectomy surgery under general anesthesia. exclusion criteria: any known allergies to the study drugs. anatomical abnormalities or infections in the serratus region. bleeding disorders e.g. thrombocytopenia, high inr, high pt in chronic liver or impaired kidney). patients on chronic pain medications or regularly receiving analgesics. pregnant or breast feeding patients. body mass index (bmi) more than 35.
postoperative hyperbaric oxygen treatments to reduce complications in diabetic patients undergoing vascular surgery

Conditions: Diabetes; Peripheral Arterial Disease; Arterial Occlusive Disease

Summary: this trial aims to evaluate if hyperbaric oxygen treatment (hbo) given postoperatively is effective in reducing healing time and wound complications after lower extremity bypass surgery in patients with diabetes. hypothesis: postoperative hbo treatment is effective in reducing complications in patients with diabetes undergoing peripheral vascular surgery


Eligibility criteria:
inclusion criteria: * patients are eligible for inclusion if the following criteria are fulfilled * informed consent obtained * scheduled for lower extremity open vascular surgery * diabetes treated with insulin or oral antidiabetic medicine * age ≥ 18 years exclusion criteria: * contraindications to hbo therapy * pregnancy (women of childbearing potential will undergo pregnancy test before inclusion) * patients already in hbo treatment * vascular reoperation * creatinine \> 250 mmol/l * nyha class iv heart failure or severe cardiopulmonary disease with desaturation judged to be incompatible with safe hbo/ placebo therapy in a monoplace chamber * clinically significant chronic obstructive pulmonary disease. * acute sepsis. * malignancy or other serious medical condition where it is likely that the patient will significantly deteriorate or not survive within the two years of follow up. * simultaneous or previous (within 30 days prior to study entry participation in a clinical study using experimental drugs or devices. * mental condition making the subject unable to understand the concepts and risk of the study

Keywords: diabetes vascular surgery hyperbaric oxygen surgical complications wound complication randomized controlled
investigating the effect of carpal tunnel syndrome on activity and participation

Conditions: Carpal Tunnel Syndrome

Summary: the aim of our study was to examine the effect of different severities of carpal tunnel syndrome on activity and participation within the framework of the international classification of functioning, disability and health (icf).

individuals between the ages of 18-65 who were diagnosed with cts in the dominant hand and who volunteered to participate in the study were included. sf-36, quick disabilities of the arm, shoulder, and hand (q-dash), michigan hand outcomes questionnaire and boston carpal tunnel questionnaire - functional status scale will be used to assess activity and participation. the questionnaires will be filled out via google forms. shapiro-wilk test will be performed to determine the distribution of the data. whether the dependent variables differ between groups will be analysed by one-way anova (continuous). for significant f-test, an additional investigation of differences between groups will be performed with gabriel's post hoc procedure.

Eligibility criteria:
inclusion criteria: * diagnosis of cts in the dominant hand * being between the ages of 18-65 * volunteering to participate in the study exclusion criteria: * having systemic inflammatory disease * having a disease that may cause polyneuropathy such as diabetes mellitus * having a pacemaker * having a disease affecting the central nervous system * having cervical radiculopathy * history of previous operation or local steroid injection due to cts
pre-exposure prophylaxis dosing in pregnancy to optimize hiv prevention (prep-p)

Conditions: Pregnancy; HIV-1-infection

Summary: this trial is a prospective, multi-center, randomized comparison study of 2 pre-exposure prophylaxis (prep) pharmacokinetic (pk) dosing regimens from 1st trimester through 12 weeks following delivery (postpartum) to achieve study objectives which include pk, safety monitoring for maternal and fetal/infant safety signals, and adherence.

study participants will be randomized to one of two parallel study arms, involving dosing of tenofovir disoproxil sodium/emtricitabine (tdf/ftc). the investigators will be recruiting and enrolling in the late 1st (preferred) and 2nd trimesters of pregnancy to capture the changes in kidney function and blood flow through the kidneys that appear to start in the late 1st trimester and are most significant in the 2nd and 3rd trimesters of pregnancy. given the unknown time frame for the return to pre-pregnancy physiologic state and the increased risk of hiv acquisition postpartum, participants will be continued on study dose prep until after participants' 1-3 week postpartum visit, after which all participants will be dispensed standard dose prep. a 6-12 week postpartum study visit will also be performed to evaluate the timing of return to non-pregnant plasma drug levels during the postpartum period. pk sampling. primary pk data will be derived from up to 7 study visits with pk sampling, including two pk visits in each trimester and postpartum. all pk visits sample blood before an observed prep dose. . safety sampling. maternal safety assessments will continue until 6 months postpartum. fetal evaluation includes non-invasive limited ultrasound (us) and biophysical profiles (bpp) at study visits and 2nd and 3rd trimester interval growth us, and chart review of all before birth assessments. at birth, the investigators will obtain cord blood plasma to assess for mitochondrial function. infant safety assessments will continue until 1 year of life. infants will undergo swaddled dual-energy x-ray absorptiometry (dxa) scans (without sedation) at 3-6, 24-28, and 50-54 weeks of age. the investigators will assess kidney function by blood sample at 3-6 weeks of life and repeated at 24-28 weeks.

Eligibility criteria:
inclusion criteria: * age 18 years or older * able to speak english, french, or spanish * able and willing to provide written informed consent * viable first (preferable) or second trimester intrauterine pregnancy * creatinine clearance \>70 ml/min * negative hiv test and no signs/symptoms of acute hiv infection, * documented negative hepatitis b virus status. exclusion criteria: * hiv positive at any time in the study. all neonates of mothers participating in the trial will be recruited, regardless of gestational age at delivery or congenital anomalies/comorbidities.

Keywords: hiv prevention healthy volunteer
motor excitability study of high definition transcranial direct current stimulation (hd-tdcs) in chronic stroke

Conditions: Stroke

Summary: high definition tdcs will be conducted to both stroke and healthy subjects on primary motor cortex area to explore the motor excitability changes before and after stimulation. in next stage, a randomized control trial with 20-session training will be conducted to evaluate the effectiveness of transient modulation of cortical excitability through multisite hd-tdcs with emg driven robot hand training, a sham stimulation with emg-driven robot hand training will be applied as control group.


Eligibility criteria:
inclusion criteria: 1. sufficient cognition to follow simple instructions, as well as understand the content and purpose of the experiment; 2. have moderate to severe motor disability at the paretic upper limb (assessed by fugl-meter assessment (fma), and action research arm test (arat)); 3. hemiparesis resulting from a single unilateral lesion of the brain with onset at least 6 months before data collection exclusion criteria: 1. severe hand spasticity, open hand wound or hand deformity; 2. visual field deficits; 3. aphasia, neglect, and apraxia; 4. history of alcohol, drug abuse or epilepsy; 5. bilateral infracts; 6. uncontrolled medical problems; 7. serious cognitive deficits \[mini-mental state examination (mmse) \< 21\]; 8. major depression 9. metal implants inside body 10. mri, tms and tdcs contraindications